Targeting RORγ inhibits the growth and metastasis of hepatocellular carcinoma
Molecular Therapy · 2024-03 · 32 (3) · 749-765
DOI: 10.1016/j.ymthe.2024.01.032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2024-03. Verfasst von Qianqian Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510006, P.R. China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Planning Project of Guangdong Province, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Approximately 80%-90% of hepatocellular carcinomas (HCC) occur in a premalignant environment of fibrosis and abnormal extracellular matrix (ECM), highlighting an essential role of ECM in the tumorigenesis and progress of HCC. However, the determinants of ECM in HCC are poorly defined. Here, we show that nuclear receptor RORγ is highly expressed and amplified in HCC tumors. RORγ functions as an essential activator of the matrisome program via directly driving the expression of major ECM genes in HCC cells. Elevated RORγ increases fibronectin-1 deposition, cell-matrix adhesion, and collagen production, creating a favorable microenvironment to boost liver cancer metastasis. Moreover, RORγ antagonists effectively inhibit tumor growth and metastasis in multiple HCC xenografts and immune-intact models, and they effectively sensitize HCC tumors to sorafenib therapy in mice. Notably, elevated RORγ expression is associated with ECM remodeling and metastasis in patients with HCC. Taken together, we identify RORγ as a key player of ECM remodeling in HCC and as an attractive therapeutic target for advanced HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510006, P.R. China.
- Clinical Research Institute, The First People's Hospital of Foshan, Foshan 528000, China.
- Department of Gastrointestinal Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120, China.
- Clinical Research Institute, The First People's Hospital of Foshan, Foshan 528000, China. Electronic address: nieych3@mail.sysu.edu.cn.
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong 510006, P.R. China; National-Local Joint Engineering Laboratory of Druggability and New Drugs Evaluation, Sun Yat-sen University, Guangzhou…
Förderung
- National Natural Science Foundation of China
- Science and Technology Planning Project of Guangdong Province
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Liu, Q., Wang, J., Sun, H., Zhang, Z., Wang, H., Ma, S., Zhang, C., Wang, Q., Cai, G., Zheng, J., Nie, Y., Liu, P., & Wang, J. (2024). Targeting RORγ inhibits the growth and metastasis of hepatocellular carcinoma. Molecular Therapy, 32(3), 749-765. https://doi.org/10.1016/j.ymthe.2024.01.032
Vancouver
Liu Q, Wang J, Sun H, Zhang Z, Wang H, Ma S, et al. Targeting RORγ inhibits the growth and metastasis of hepatocellular carcinoma. Molecular Therapy. 2024;32(3):749-765. doi:10.1016/j.ymthe.2024.01.032
BibTeX
@article{Liu2024,
author = {Liu, Qianqian and Wang, Junhua and Sun, Huizi and Zhang, Zhenhua and Wang, Hong and Ma, Shuai and Zhang, Chenxi and Wang, Qianqian and Cai, Guodi and Zheng, Jianwei and Nie, Yichu and Liu, Peiqing and Wang, Junjian},
title = {Targeting RORγ inhibits the growth and metastasis of hepatocellular carcinoma},
journal = {Molecular Therapy},
year = {2024},
volume = {32},
number = {3},
pages = {749--765},
doi = {10.1016/j.ymthe.2024.01.032}
}
EUVIMED